bioLIVE
The market size of China’s bio drugs is predicted to reach RMB 326.9 billion in 2021, with a YOY increasing rate of 17.99%, which signposts the golden age of the Chinese biopharmaceutical industry. bioLIVE China 2020, together with its concurrent high-end conference Bio S&T, will focus on the most heated subjects on life science, life technology and innovative drugs, and facilitate a one-stop platform for biopharmaceutical manufacturers and technical service providers.
The exhibition is a feast of the practitioners in pharmaceutical industry, which gathers high-quality enterprises at home and abroad and attracts worldwide customer groups. As an exhibitor, we appreciate it much to the organizer for providing such a global platform for we exhibitors, so that we have the opportunity to show our business and products. It also creates many chances of international cooperation, promoting the internalization process of China’s pharmaceutical industry.
Why Visit?
- Show cutting-edge products and technology in biopharmaceutical industry
- Gather more than 150 biopharmaceutical enterprises at home and abroad to show the latest technologies and hot spots from multiple perspectives
- Over 30 concurrent pharma R&D events and more than 80 eminent speakers from biopharmaceutical industry to deliver latest trends
Exhibitor Profiles
Biologics and New Therapies
- Recombinant Protein
- Polypeptide
- Nucleic Acid
- Vaccines
- Plasma
- Antibodies
- Cell & Gene Therapy
- Tumor Immunotherapy
- Stem Cell & iPS
Bioprocessing, Manufacturing and Solutions
- Cell Culture Media
- Biological Reagents
- Laboratory Consumables
- Bioreactors
- Bioseparation
- Protein Purification
- Bioprocessing
- Software & Service
Biotechnology and R&D services
- Molecular Biology
- Cell Biology
- Proteomics & Metabolomics
- Biotechnology Service Platform
- Detection Services
- Biology Information Services
- Drug R&D and Manufacturing
- Clinical Research
/Pharma-Outlook-2020.png)
